Section Editors

  • Michael Aschner, Vanderbilt University
  • Phil Biggin, University of Oxford
  • Lucio Guido Costa, University of Washington
  • David H Farb, Boston University School of Medicine
  • Giorgio Palu, University of Padova

Executive Editor

  • Christopher Morrey, BioMed Central

Articles

There has been an error retrieving the data. Please try again.
  • Image attributed to: BMC Pharmacology and Toxicology 2013, 14:17

    Label-free sorting of opioid ligands is right on-target

    A label-free integrative pharmacology on-target (iPOT) approach systematically surveys a library of opioid ligands against the opioid receptor family and effectively sorts them into distinct clusters based on their binding and functional selectivity.

    BMC Pharmacology and Toxicology 2013, 14:17
  • Image attributed to: BMC Pharmacology and Toxicology 2013, 14:11

    High-throughput approach to study DNA hypomethylation

    3D quantitative DNA methylation imaging enables the quantification of dose-dependent drug-induced spatial progression of DNA demethylation in cell nuclei, independent from interphase cell-cycle stages in conjunction with cytotoxicity.

    BMC Pharmacology and Toxicology 2013, 14:11
  • Image attributed to: Wikimedia Commons by National Human Genome Research Institute

    Nematode model of early exposure to genotoxicants

    Exposure of developing Caenorhabditis elegans to ultraviolet C radiation results in decreased ATP levels and oxygen consumption in later life, suggesting that early life contact with mitochondrial genotoxicants may lead to time-delayed mitochondrial dysfunction.

    BMC Pharmacology and Toxicology 2013, 14:9
  • Image attributed to: BMC Pharmacology and Toxicology 2013, 14:3

    Identification of a small molecule inhibitor of IKKβ

    A benzoic acid derivative, identified by high-throughput virtual screening and molecular modeling, is capable of inhibiting IKKβ phosphorylation activity in vitro, and blocking IκBα protein degradation together with subsequent NF-κB  activation in human cells.

    BMC Pharmacology and Toxicology 2013, 14:3
  • View more articles  

RSS

Comments

View more comments

Scope

BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials.

It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.

Latest review

Review Highly Accessed

Role of astrocytes in manganese mediated neurotoxicity

Marta Sidoryk-Wegrzynowicz and Michael Aschner

BMC Pharmacology and Toxicology 2013, 14:23 (18 April 2013)

Editors' Profile

Lucio G. Costa and Michael Aschner

Lucio G. Costa and Michael Aschner

Lucio G. Costa (left) is currently Professor of Environmental and Occupational Health Sciences at the School of Public Health at the University of Washington. Dr Costa is a renowned neurotoxicologist whose research interests are focused on understanding the role of neurotoxic substances in neurodevelopmental disorders and other neurological, neuropsychiatric and neurodegenerative diseases. Michael Aschner (right) is the Gray E. B. Stahlman Professor of Pediatrics and Pharmacology at Vanderbilt University School of Medicine as well as a Senior Investigator at the Kennedy Center for Research on Human Development. Dr Aschner's research group has a particular interest in the neurobiology and physiology of astrocytes and the signaling mechanisms associated with central nervous system injury. Dr Costa and Dr Aschner are Section Editors for the Toxicology section in BMC Pharmacology and Toxicology. Read more about the key issues in this field and the manuscripts they would like to see submitted to the section in their interview with the journal.

"We are interested in original research and review papers that address the interactions of chemicals with biological systems. The manuscripts may include basic research of molecular mechanisms underlying normal and abnormal physiology to define novel therapeutic targets; translational research to adapt observations from the laboratory to patients; clinical research to examine the behavior of novel therapeutics in humans; basic research to identify molecular mechanisms and targets of xenobiotics; and population research to identify health outcomes associated with exposures to environmental agents and xenobiotics."

BMC Pharmacology

BMC Pharmacology and Toxicology assimilated the Editorial boards and history of BMC Pharmacology and BMC Clinical Pharmacology on fusion of the journals in 2012. The full archive of BMC Pharmacology is available from its own archive website, and the objectives and aspirations of the merged journal are explained in the editorial that accompanied the fusion. The full archive of BMC Clinical Pharmacology is available here.